Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Indian journal of pharmacology - 53(2021), 3 vom: 25. Mai, Seite 246-247 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vityala, Yethindra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 07.07.2021 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4103/ijp.IJP_33_21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32717059X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32717059X | ||
| 003 | DE-627 | ||
| 005 | 20231225200201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/ijp.IJP_33_21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM32717059X | ||
| 035 | |a (NLM)34169913 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vityala, Yethindra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a itolizumab |2 NLM | |
| 650 | 7 | |a XQQ2RHV14N |2 NLM | |
| 700 | 1 | |a Tagaev, Tugolbai |e verfasserin |4 aut | |
| 700 | 1 | |a Mamatov, Sagynali |e verfasserin |4 aut | |
| 700 | 1 | |a Aidarov, Ziiabidin |e verfasserin |4 aut | |
| 700 | 1 | |a Harinath, Panchadcharam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of pharmacology |d 1982 |g 53(2021), 3 vom: 25. Mai, Seite 246-247 |w (DE-627)NLM078779812 |x 1998-3751 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:3 |g day:25 |g month:05 |g pages:246-247 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/ijp.IJP_33_21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 3 |b 25 |c 05 |h 246-247 | ||